



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2016-17

Date: 12th August, 2016

To,
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001
BSE CODE - 524348
BSE ID - AARTIDRUGS

National Stock Exchange of India
Limited
"Exchange Plaza",
Bandra - Kurla Complex,
Bandra(E), Mumbai - 400 051
NSE CODE: AARTIDRUGS

Sub: Outcome of Board Meeting held today i.e. 12th August, 2016 pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Dear Sir,

Pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we inform you that the Board of Directors at its Meeting held today i.e. Friday, 12th August, 2016 had *inter-alia* considered and approved the Audited Financial Results (Standalone & Consolidated) for the Quarter ended 30th June, 2016. Accordingly, please find enclosed herewith Statement of Audited Financial Results (Standalone & Consolidated) for the Quarter ended on 30th June, 2016 alongwith report of the Statutory Auditors.

The meeting commenced at 12 noon and concluded at 2.30 p.m.

The above is for your kind information and records. You are requested to acknowledge the receipt.

Thanking you,
Yours faithfully,

For Aarti Drugs Limited

Vibhav S. Ranade
Company Secretary & Compliance Officer



Encl: A/A



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com
CIN NO : L37060MH1984PLC055433

AARTI DRUGS LIMITED									
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUN, 2016									
Sr. No.	Particulars	Standalone				(Rs. in lacs except for share data)			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		30th Jun 2016 (Audited)	31st Mar 2016 (Audited)	30th Jun 2015 (Audited)	31st Mar 2016 (Audited)	30th Jun 2016 (Audited)	31st Mar 2016 (Audited)	30th Jun 2015 (Audited)	31st Mar 2016 (Audited)
1	Income from Operations								
	(a) Gross Sales / Income from Operations								
	Less : Excise Duty & Sales Tax	29,484	32,376	28,640	116,610				
	(a) Net Sales / Income from Operations (Net Of Excise Duty & Sales Tax)	2,586	2,681	2,310	9,536	31,549	33,975	30,602	
	(b) Other Operating Income	26,899	29,695	26,329	107,073	2,399	2,578	2,274	
	Total income from operations (net)	13	51	38	476	29,150	31,397	28,328	
		26,912	29,746	26,367	107,550	38	64	45	
2	Expenditure								
	(a) Cost of materials consumed								
	(b) Purchase of stock-in-trade	19,559	16,235	18,979	68,298	20,950	17,133	20,760	
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	434	514	971	3,652	789	901	934	
	(d) Employee benefits expense	(2,417)	3,551	(2,481)	(525)	(2,605)	3,523	(2,467)	
	(e) Depreciation and Amortisation Expense	1,150	1,119	994	4,136	1,261	1,221	1,065	
	(f) Other expenses	920	907	867	3,558	962	935	889	
	Total expenses	3,804	3,952	3,553	14,818	3,980	4,108	3,659	
		23,450	26,279	22,883	93,938	25,336	27,821	24,839	
3	Profit from Operations before Other Income, finance costs and exceptional items								
4	Other Income (1-2)	3,462	3,466	3,484	13,612	3,851	3,640	3,534	
5	Profit from ordinary activities before finance cost and exceptional items (3+4)	-	-	-	-	-	-	-	
6	Finance costs (interest)	3,462	3,466	3,484	13,612	3,851	3,640	3,534	
7	Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	948	1,125	1,029	4,328	996	1,151	1,044	
8	Exceptional Items	2,514	2,341	2,455	9,284	2,855	2,489	2,489	
9	Profit from Ordinary Activities before Tax (7-8)	-	-	-	-	-	-	-	
		2,514	2,341	2,455	9,284	2,855	2,489	2,489	
10	Tax Expenses								
	Provision for Taxation - Current	780	630	750	2,655	861	630	750	
	- MAT Credit Entitlement	640	490	610	2,115	713	490	610	
	- Earlier year	-	-	-	-	-	-	-	
	Provision for Deferred Taxation	-	-	-	-	-	-	-	
		140	140	140	540	148	140	140	
11	Net profit from ordinary Activities after Tax (9-10)	1,734	1,711	1,705	6,629	1,994	1,859	1,739	
12	Extraordinary items	-	-	-	-	-	-	-	
13	Net Profit for the Period (11+12)	1,734	1,711	1,705	6,629	1,994	1,859	1,739	
14	Shares of Profit/ (Loss) of associates	-	-	-	-	-	-	-	
15	Minority Interest	-	-	-	-	-	-	-	
16	Net Profit for the Period after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	1,734	1,711	1,705	6,629	1,994	1,859	1,739	
17	Paid-up Equity Share Capital of Rs.10/- each.								
18	Reserves & Surplus (excluding revaluation reserves)	2,422	2,422	2,422	2,422	2,422	2,422	2,422	
19	Earning per share								
	Diluted E P S (in Rs.)								
	(of Rs. 10 /- each) (not annualised)								
	(a) Basic & Diluted (before extraordinary items)	7.16	7.07	7.04	27.37	8.23	7.68	7.18	
	(b) Basic & Diluted (after extraordinary items)	7.16	7.07	7.04	27.37	8.23	7.68	7.18	

Notes :

- The above results for the quarter ended 30th Jun, 2016 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 12th Aug, 2016.
- Company is operating as a single segment company, engaged in pharmaceutical Business.
- Figures for the previous period have been regrouped or rearranged wherever necessary.
- The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.com and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors.

Place: Mumbai

Date: 12th August, 2016



For AARTI DRUGS LIMITED

Harshit M. Savla
HARSHIT M.SAVLA
JT.MANAGING DIRECTOR

Regd. Office : Plot No. N-198, MIDC, Tarapur, Tal-Palghar, Dist. Palghar. 401 506



gokhale & sathe
(regd.)
chartered accountants

308/309, udyog mandir no. 1,
7-c, bhagoji keer marg,
mahim, mumbai 400 016.

Auditor's Report on Quarterly Standalone Financial Results of AARTI DRUGS LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors of AARTI DRUGS LIMITED

We have audited the quarterly standalone financial results of AARTI DRUGS LIMITED ('the Company') for the quarter ended June 30, 2016, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

These quarterly standalone financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, on Interim Financial Reporting, specified under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.





In our opinion and to the best of our information and according to the explanations given to us these quarterly standalone financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended June 30, 2016.

For GOKHALE & SATHE
CHARTERED ACCOUNTANTS
Firm Registration No.: 103264W

CA TEJAS PARIKH
PARTNER
M. No. 123215
Mumbai,

Dated: August 12, 2016.





gokhale & sathe

(regd.)

chartered accountants

308/309, udyog mandir no. 1,
7-c, bhagoji keer marg,
mahim, mumbai 400 016.

Auditor's Report on Quarterly Consolidated Financial Results of AARTI DRUGS LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of AARTI DRUGS LIMITED.

We have audited the quarterly consolidated financial results of AARTI DRUGS LIMITED ("the Company") for the quarter ended June 30, 2016, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

These quarterly consolidated financial results have been prepared from consolidated interim financial statements, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial results based on our audit of such consolidated interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, on Interim Financial Reporting, specified under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

We did not audit financial statements/financial information of one subsidiary whose financial statement/financial information reflect total revenues of Rs.3891.87 lakhs for the quarter ended June 30, 2016 as considered in the consolidated financial statements. These financial statements/ financial information have been audited by other auditor whose report have been furnished to us and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of its subsidiary is based solely on the report of the other auditor.





In our opinion and to the best of our information and according to the explanations given to us these quarterly consolidated financial results:

- (i) include the quarterly financial results of its only subsidiary, Pinnacle Life Science Private Limited
- (ii) have been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (iii) give a true and fair view of the consolidated net profit and other financial information for the quarter ended June 30, 2016.

For GOKHALE & SATHE
CHARTERED ACCOUNTANTS
Firm Registration No.: 103264W

CA TEJAS PARIKH
PARTNER
M. No. 123215
Place: Mumbai
Date: August 12, 2016.

